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Abstract
Aims To estimate remaining life expectancy (RLE), quality-adjusted life expectancy (QALE), causes of death and lifetime
cumulative incidence of microvascular ⁄macrovascular complications of diabetes for youths diagnosed with Type 2 diabetes.
Methods A Markov-like computer model simulated the life course for a hypothetical cohort of adolescents ⁄young adults in
the USA, aged 15–24 years, newly diagnosed with Type 2 diabetes following either conventional or intensive treatment based
on the UK Prospective Diabetes Study. Outcomes included RLE, discounted QALE in quality-adjusted life years (QALYs),
cumulative incidence of microvascular ⁄macrovascular complications and causes of death.
Results Compared with a mean RLE of 58.6 years for a 20-year-old in the USA without diabetes, conventional treatment
produced an average RLE of 43.09 years and 22.44 discounted QALYs. Intensive treatment afforded an incremental
0.98 years and 0.44 discounted QALYs. Intensive treatment led to lower lifetime cumulative incidence of all microvascular
complications and lower mortality from microvascular complications (e.g. end-stage renal disease (ESRD) death 19.4% vs.
25.2%). Approximately 5% with both treatments had ESRD within 25 years. Lifetime cumulative incidence of coronary
heart disease (CHD) increased with longer RLE and greater severity of CHD risk factors. Incorporating disutility (loss in
health-related quality of life) of intensive treatment resulted in net loss of QALYs.
Conclusions Adolescents ⁄young adults with Type 2 diabetes lose approximately 15 years from average RLE and may
experience severe, chronic complications of Type 2 diabetes by their 40s. The net clinical benefit of intensive treatment may
be sensitive to preferences for treatment. A comprehensive management plan that includes early and aggressive control of
cardiovascular risk factors is likely needed to reduce lifetime risk of CHD.
Diabet. Med. 29, 453–463 (2012)
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Introduction
Type 2 diabetes in youth has drawn increasing attention as the
increase in childhood obesity contributes to its rising incidence
and prevalence [1–5]. Longitudinal data from Pima Indians
suggest that longer duration of diabetes among those with
youth-onset diabetes contributes to higher incidence of end-
stage renal disease (ESRD) and morbidity and mortality in
middle age [6]. However, there are little data regarding the
natural history of Type 2 diabetes diagnosed among youth in
the general US population.
Understanding the natural history of Type 2 diabetes in
youth has implications for clinical management, research and
policy. Epidemiological studies suggest that youths with Type 2
diabetes are at risk for microvascular and macrovascular
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complications [7]. However, it may take decades to understand
these risks. Several models (e.g. [8–11]) have projected out-
comes for diabetes in adults, but these projections cannot be
applied to adolescents ⁄young adults, whose risks for diabetes
complications and preferences for health states and treatment
may differ. Narayan et al. [12] have previously modelled the
lifetime risk of diabetes for individuals born in 2000, and life
years and quality-adjusted life years (QALYs) lost because of
diabetes by age at diagnosis. However, this model does not
address the individual contributions of microvascular or mac-
rovascular complications to these outcomes. We have, there-
fore, adapted an adult model of Type 2 diabetes progression,
the CDC-RTI Diabetes Cost-Effectiveness Model [10,13] (‘RTI
Model’), for an adolescent ⁄young adult US cohort (‘Youth
Model’) to describe the morbidity, mortality, and health-related
quality of life experienced by youths diagnosed with Type 2
diabetes following either ‘conventional’ or ‘intensive’ glycaemic
control introduced at diagnosis.
Methods
Markov models, or state-transition models, can address com-
plex diseases such as diabetes because they can capture the
course of benefits and risks of treatment over time. These
models represent mutually exclusive health states, and a cohort
of people are initially distributed among these health states
mirroring their prevalence in similar real-world populations
[14]. With each cycle, people have a probability of remaining in
their current state or transitioning to a different one [14]. Our
variant of this modelling incorporates interdependencies among
diabetes complications and time-varying transition probabili-
ties to examine the natural history of Type 2 diabetes in youth.
Model structure
The RTI Model is a Markov-like model that includes cohorts
in 10-year age groups, between 25 and 94 years [10,13]. In
our Youth Model, we adapted the RTI Model to include an
adolescent ⁄young adult cohort, aged 15–24 years, at diabetes
diagnosis. The RTI Model includes transition probabilities and
intervention effects based on the outcomes of Type 2 diabetes
patients in the UK Prospective Diabetes Study (UKPDS) [15].
In brief, the UKPDS was a randomized, controlled trial for
newly diagnosed Type 2 diabetes patients between 25 and
65 years of age with a fasting glucose > 6 mmol ⁄ l
(108 mg ⁄dl) recruited in the UK between 1977 and 1991 [15].
The UKPDS trial compared ‘intensive’ treatment with either
insulin or a sulphonylurea with ‘conventional’ treatment with
diet. Details of the RTI Model and its use of UKPDS data
have been previously described [10,13]. Technical Report S1
(see Supporting Information) provides additional information
about the Youth Model adaptation of the RTI Model.
In the Youth Model simulation, patients diagnosed with
diabetes progress simultaneously through disease paths repre-
senting nephropathy, neuropathy, retinopathy, coronary heart
disease (CHD) and stroke. Health-state transitions may vary
according to clinical and demographic characteristics: time
since diagnosis, time between onset and diagnosis, age, sex,
race ⁄ ethnicity, glycaemic control, smoking, hypertension and
hypercholesterolemia. Patients can die from lower extremity
amputation, ESRD, CHD, stroke, or non-diabetes related
causes. Mortality rates from ESRD and other causes are a
function of age, sex, and race ⁄ ethnicity.
Sources for adolescent ⁄ young adult-specific estimates
To create the Youth Model with a 15- to 24-year-old cohort,
all RTI Model parameters were reviewed and replaced with
age-specific estimates, when appropriate and available. Key
updated assumptions included hazard rates for health-state
transitions, initial prevalence of complications at diagnosis,
glycaemic control parameters, and utilities (Table 1).
To inform parameters for the Youth Model, a systematic
literature review was conducted in March 2007 to identify
studies examining glycaemic control and microvascular and
macrovascular outcomes in adolescents ⁄young adults with
Type 2 diabetes diagnosed before age 25 years. A total of 817
relevant studies were identified of which 110 articles and dis-
sertations ⁄ theses and 12 abstracts were reviewed. Targeted
searches of the published literature through December 2009
were performed to identify relevant new information. Data
from the SEARCH for Diabetes in Youth study was used
extensively for the assumptions in the Youth Model [1–5,16–
20]. An expert panel convened in March 2008 informed key
estimates in the Youth Model for which there remained
ongoing uncertainty and limited or no available data.
Cohort description and health-state transitions
Based on the structure of the RTI Model, the 15- to 24-year-
old newly diagnosed Type 2 diabetes cohort had to be
subdivided by sex, race ⁄ ethnicity, hypertension, cholesterol
and smoking status. These groupings were based upon the
2006 US Census [21] and published data [1–5,19,20] (see
Supporting Information, Technical Report S1, eTable 30).
Incidence of Type 2 diabetes was based on the SEARCH
study [1–5]. The cohort based on these data included
approximately 3500 adolescents ⁄young adults with newly
diagnosed Type 2 diabetes. Available data suggest that the
pace of b-cell failure in youths with Type 2 diabetes is faster
than that observed in adults [22]. For the Youth Model, we
assumed onset of diabetes was less than 1 year from diag-
nosis, and therefore, at diagnosis for the purpose of model-
ling. Very low rates of screening-detected diabetes in youths
[23,24] support this assumption. Weiss et al. [25] also
showed that 24.2% of obese youths with impaired glucose
tolerance screened with an oral glucose tolerance test at
18- to 24-month intervals progressed to Type 2 diabetes over
an average follow up of 20.4  10.3 months. Therefore,
0–2 years from onset to diagnosis was used as the range for
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sensitivity analysis. Based on input from our expert panel
and research suggesting that the UKPDS risk engine may be
preferable to the Framingham risk equation in younger adult
populations with Type 2 diabetes [26], we chose to use the
UKPDS risk engine to calculate risk of CHD for the base
case analysis.
Hazard rates for health-state transitions for microvascular
complications among adolescents ⁄young adults with Type 2
Table 1 Youth model parameters and ranges for sensitivity analyses
Parameter
Intensive
glycaemic
control
Conventional
glycaemic
control
Beta
exponent
[10]
Ranges for
sensitivity
analysis
Glycaemic controla
Initial HbA1c at onset,
% [37]
7.4 (57 mmol ⁄mol) 7.4 (57 mmol ⁄mol) N ⁄A 6.8 [10]–10.9 [43] (51–96
mmol ⁄mol)
Annual rate of HbA1c change before
treatment, % [18]
0.24 0.24 N ⁄A N ⁄A
Years between onset and diagnosis* 0 0 N ⁄A 0–2 [25]
One-time initial treatment effect,
HbA1c % [10]
)2.9 )2.0 N ⁄A N ⁄A
Annual rate of HbA1c change after
treatment, % [18]
0.24 0.24 N ⁄A 0.18–0.72 [18]
0.20 [10] Intensive
Minimum HbA1c with ⁄without treat-
ment, % [10]
6.0 (42 mmol ⁄mol) 6.0 (42 mmol ⁄mol) N ⁄A N ⁄A
Maximum HbA1c with treatment, %
[10]
9.0 (75 mmol ⁄mol) 11.0 (97 mmol ⁄mol) N ⁄A Conventional 13 (119 mmol ⁄mol)
Prevalence of complications
at diagnosisb, % of cohort
Microalbuminuria [16]§ 16 16 N ⁄A 0–40§
Retinopathy [10]§ 0 0 N ⁄A 0–10§
Peripheral neuropathy [10]§ 0 0 N ⁄A 0–10§
Coronary heart disease [10] 0 0 N ⁄A N ⁄A
Stroke [10] 0 0 N ⁄A N ⁄A
Adolescent utilities [27]kc
End-stage renal disease 0.511 0.511 N ⁄A 0.005–0.999 [27]
Adult 0.61 [10], 0.35 [34]
Lower extremity amputation 0.557 0.557 N ⁄A 0.001–0.99 [27]
Adult 0.8 [10], 0.55 [34]
Blindness 0.547 0.547 N ⁄A 0.02–1.0 [27]
Adult 0.69 [10], 0.38 [34]
Angina ⁄ coronary heart disease 0.587 0.587 N ⁄A 0.03–0.995 [27]
Adult angina 0.947 [10], 0.64 [34]
Adult coronary heart disease 0.88
[10]
Stroke 0.587 0.587 N ⁄A 0.03–0.995 [27]
Adult 0.5 [10], 0.31 [34]
Intensive glycaemic control (mean
difference vs. diet)–
)0.063 N ⁄A N ⁄A Adult –0.21 [34]
Hazard rates (HR)d
Normal to microalbuminuria Calculated# 0.1455 4.28 Faster nephropathy progression,
HR = 0.42; slower progression to
microalbuminuria, HR = 0.042
Normal to retinopathy requiring pho-
tocoagulation
Calculated# 0.006 2.74 Faster retinopathy progression,
HR = 0.04; slower progression to
retinopathy, HR = 0.001
Normal to peripheral neuropathy Calculated# 0.0085 3.07 Faster neuropathy progression,
HR = 0.4702; slower progression
to neuropathy, HR = 0.0019
Numbers in square brackets are references. Superscript letters refer to Tables from Technical Report S1 in the Supporting Information :
aeTables 21a,b; beTables 1a–5a; ceTable 32; deTables 6a–8a for base case HR; eTable 22 for beta exponent; and eTable 33 for sensitivity
analyses. *Assumption supported by [23–25]. Assumption supported by [18]. §Discussed and approved by Expert Panel. kBased on N = 66
valid respondents. –Disutility compared with conventional treatment (i.e. the decrease in utility of intensive treatment with insulin vs.
conventional treatment with diet therapy). #Hazard rate for intensive treatment is derived in the model by the impact of the beta exponent
on the conventional treatment HR. NA, not applicable.
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diabetes (Table 1) were calculated from the weighted average
of hazard rates derived from relevant studies identified through
the systematic review. A detailed description of these studies is
included in Technical Report S1 (eTables 6a–8a).
Interventions
The Youth Model predicts outcomes for those receiving either
conventional or intensive glycaemic control based on the out-
comes of these treatments in the UKPDS [15]. Specifically, the
Youth Model assumes that conventional glycaemic control
achieves an average HbA1c of 63 mmol ⁄mol (7.9%) over a
median of 10 years and that intensive glycaemic control
reduces the average HbA1c over a median of 10 years to
53 mmol ⁄mol (7%). Glycaemic control affects transition
probabilities and, therefore, the cumulative incidence of com-
plications and deaths from complications (Table 1). Other
interventions were retained from the RTI Model [10] (discussed
in Technical Report S1 sections 2.2.–2.4.) and applied to all
patients in the Youth Model as appropriate regardless of their
treatment for diabetes. Specifically, patients with hypertension
receive moderate hypertension control, which reduces CHD by
13% and stroke by 17%; patients with hypercholesterolaemia
(total cholesterol ‡ 200 mg ⁄dl) receive statin therapy, which
reduces CHD by 31% and progression by 25%; and smokers
receive brief counselling with a marginal quit rate of 1.86%
and relapse rate of 45%. Quitters experience a reduction in
CHD and stroke risk. One year after quitting, the risk is halved
and then declines linearly until reaching the risk of a never-
smoker at year 15. Adherence to treatments in the Youth
Model is assumed to be comparable to that of adults.
Utilities
Utilities for diabetes complications and treatments in the
Youth Model were based on adolescents with or at risk of
Type 2 diabetes (Table 1). Utilities represent health-related
quality of life associated with health states where 1.0 repre-
sents perfect health and 0 represents dead. We interviewed 70
overweight ⁄obese, 12- to 18-year-old youths with, or at risk
of Type 2 diabetes, in-person between April 2006 and
February 2008 using the standard gamble to elicit preferences
for seven hypothetical Type 2 diabetes health states and
treatments [27]. For the base case, utility of intensive treat-
ment was set at 1.0, reflecting no disutility (i.e. loss in health-
related quality of life). To determine the disutility associated
with intensive treatment in sensitivity analyses, we assumed
that intensive treatment for youths with Type 2 diabetes
included insulin and compared it with conventional treatment
with diet (Table 1).
Primary analysis
For a hypothetical cohort of 15- to 24-year-olds with newly
diagnosed Type 2 diabetes, primary outcomes were remaining
life expectancy (RLE), quality-adjusted life expectancy
(QALE), causes of death and cumulative incidence of micro-
vascular and macrovascular complications. Remaining life
expectancy was defined as remaining life years, undiscounted,
from diagnosis. QALE, defined in QALYs, was discounted
using a 3% annual discount rate in the base case and included
adolescent utilities.
Sensitivity analyses
One-way sensitivity analyses, changing assumptions about one
parameter, were performed for conventional glycaemic control
(QALYs) and the incremental benefit of intensive compared
with conventional glycaemic control (difference in QALYs),
presented as percent change from the base case. Parameters
evaluated included: prevalence of complications at diagnosis;
rates of microvascular disease progression; years from onset to
diagnosis; HbA1c at diagnosis and maximum HbA1c under
conventional treatment; rate of HbA1c change; estimate for
abnormal blood pressure; prevalence of hypertension; inter-
ventions such as intensive hypertension control; utilities; CHD
risk; discount rate; intensive glycaemic control impact on CHD
and variation of individual CHD risk parameters. The impact
of microvascular and macrovascular disease progression on
cumulative incidence of diabetes complications was also eval-
uated. Tornado diagrams were used to show those individual
parameters that resulted in at least a  0.5% change in QALYs
resulting from conventional glycaemic control and a  2.5%
change in the incremental benefit of intensive compared with
conventional glycaemic control (difference in QALYs).
In addition, a number of multi-way sensitivity analyses were
performed to evaluate the impact of changes in combinations of
key model parameters. Specifications for these analyses are
detailed in eTable 34 in Technical Report S1.
Results
Remaining life expectancy and quality-adjusted life
expectancy
Compared with an average 20-year-old without diabetes in the
USA with RLE of 58.6 years [28], for the US population of
newly diagnosed Type 2 diabetes patients between 15 and
24 years old, conventional treatment in the Youth Model pro-
duced a RLE of 43.09 years, QALE of 39.32 QALYs
(undiscounted) and 22.44 QALYs (3% discounted). The QALY
gains and losses can reflect changes in quality of life throughout
the lifetime, not just related to an extension in life expectancy.
Intensive treatment afforded an incremental 0.98 years, 1.32
QALYs (undiscounted), and 0.44 QALYs (discounted). How-
ever, when the disutility of intensive treatment, assumed to in-
clude insulin, relative to a conventional treatment with diet
therapy was included in the Youth Model, those treated inten-
sively lost 2.29 QALYs (undiscounted) and 1.35 QALYs
ª 2011 The Authors.
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(discounted) and intensive treatment resulted in a net loss of
QALYs compared to conventional treatment (Table 2).
Incidence of complications and death
Those treated intensively had lower lifetime cumulative inci-
dence of all microvascular complications (Fig. 1). The diver-
gence in cumulative incidence of microvascular complications
occurred between intensively treated and conventionally trea-
ted patients after 20–30 years of diabetes. Figure 2 highlights
this pattern for ESRD and blindness. The result was lower
mortality from microvascular complications among those
treated intensively (e.g. ESRD death 19.4% vs. 25.2%).
Greater survival among those treated intensively for 30–
40 years contributed to higher lifetime cumulative incidence of
stroke (32.4% vs. 29.8%) and CHD (36.1% vs. 34.0%) and
higher mortality from cardiovascular complications (e.g. death
from CHD 25.1% vs. 23.1%) in this group (Fig. 1). Based on
our youth cohort of approximately 3500 people with newly
diagnosed Type 2 diabetes annually, the number of adolescents
and young adults annually, who would experience each
diabetes complications in their lifetime is presented in Table 2.
The model predicted that microalbuminuria would be pres-
ent in nearly the whole cohort by the end of life regardless of
treatment (Fig. 1). However, there was a higher lifetime
cumulative incidence of ESRD in the conventional group
(29.0% vs. 22.3%). After 25 years, at least 5% in both groups
had ESRD and after 35 years, at least 10%. Lifetime cumula-
tive incidence of blindness was 13.8% and 18.5% in the
intensive and conventional groups, respectively. However, after
35 years, at least 10% in both groups experienced blindness.
Lower extremity amputation occurred infrequently with life-
time cumulative incidence of 3.6% and 4.7% in intensive and
conventional groups, respectively.
Sensitivity analyses
Changing the Youth Model assumptions had only modest
impact on conventional treatment outcomes. The only change
that produced more than a 10% change in QALYs was the
discount rate, which resulted in 16.92 QALYs with a 5% dis-
count rate and 39.32 QALYs with 0%. Increasing the rate of
progression of microvascular complications, particularly reti-
nopathy, reduced the benefit of conventional treatment
(Fig. 3a). Change in the discount rate also had the most sig-
nificant impact on the incremental benefit of intensive treat-
ment. A 0% discount rate produced an incremental benefit of
1.32 QALYs (as above) vs. 0.23 QALYs with 5%. Intensive
treatment was more favourable if HbA1c at diagnosis was
higher, if HbA1c increase per year was higher, if retinopathy
progression was faster or if adolescent utilities for diabetes
complications were lower (Fig. 3b). In our base case analysis,
nephropathy was the only microvascular complication for
which we assumed a faster initial rate of disease progression in
US youths than in adults [10] (Table 1). Slowing the rate of
progression to microalbuminuria increased the benefit of con-
ventional treatment by less than 5% (Fig. 3a) and reduced the
incremental benefit of intensive treatment by approximately
10% (Fig. 3b). In contrast, assuming a faster rate of progres-
sion of nephropathy for those with hypertension decreased the
Table 2 Youth model outcomes: remaining life years, quality adjusted life expectancy and complications
Treatment
Outcome
Conventional
glycaemic control
Intensive
glycaemic control
Incremental benefit
of intensive treatment
Remaining life years (undiscounted) 43.09 44.07 0.98
QALYs (undiscounted) without loss
in HRQOL for intensive treatment
39.32 40.64 1.32
QALYs (undiscounted) with loss in
HRQOL for intensive treatment
vs. conventional (diet therapy)
39.32 38.35 )0.96
QALYs (discounted 3%) without
loss in HRQOL for intensive treat-
ment
22.44 22.88 0.44
QALYs (discounted 3%) with loss in
HRQOL for intensive treatment vs.
conventional (diet therapy)
22.44 21.53 )0.91
Adolescents and young adults annu-
ally, who experience each diabetes
complications in their lifetime*
End-stage renal disease (n) 1015 781 234
Coronary heart disease (n) 1190 1264 –74
Blindness (n) 648 483 165
Lower extremity amputation (n) 165 126 39
*Based on a yearly cohort size of 3500 as described in the methods. HRQOL, health-related quality of life; QALY, quality-adjusted life year.
ª 2011 The Authors.
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benefit of conventional treatment by less than 5% (Fig. 3a) and
increased the incremental benefit of intensive treatment by
approximately 15% (Fig. 3b). When considering the disutility
of treatment, intensive treatment would not be considered
effective (i.e. fewer QALYs were produced compared with
conventional treatment) if its utility was more than 0.02 lower
than conventional treatment.
Compared with our base case, assuming a slower rate of
progression to microalbuminuria (Table 1) led to a slightly
lower lifetime cumulative incidence of microalbuminuria
(conventional 87.4% vs. intensive 72.6%) and to lower rates of
nephropathy and ESRD (20.9% vs. 14.2%). This was a dif-
ference of approximately 8% from our base case, but a delay of
only 3 years (28 years diabetes duration) for at least 5% in
both groups to have ESRD. Using the slower, adult rate of
progression to microalbuminuria [10] for patients after
10 years of diabetes, lifetime cumulative incidence of microal-
buminuria was also lower (conventional 92.3% vs. intensive
82.6%). In contrast to microalbuminuria, progression to reti-
nopathy in youths was assumed to occur at a slower rate than
FIGURE 1 Lifetime cumulative incidence of diabetes complications and cause of death. All patients were newly diagnosed as having Type 2 diabetes
between 15 and 24 years of age and received conventional or intensive glycaemic control. The upper set of bars represent causes of death, and the lower set
represent diabetes complications. Open bars, intensive glycaemic control; closed bars, conventional glycaemic control.
FIGURE 2 Progression of end-stage renal disease (ESRD) and blindness by diabetes duration. All patients were newly diagnosed as having Type 2 diabetes
between 15 and 24 years of age and received conventional or intensive glycaemic control. Open squares, cumulative incidence of blindness with intensive
treatment; closed squares, cumulative incidence of blindness with conventional treatment; open triangles, cumulative incidence of ESRD with intensive
treatment; closed triangles, cumulative incidence of ESRD with conventional treatment.
ª 2011 The Authors.
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in adults (Table 1). Using the faster, adult rate of progression
from normal to retinopathy [10] for patients after 10 years of
diabetes, lifetime cumulative incidence of blindness increased
(conventional 27.0% vs. intensive 20.1%). A higher cumulative
incidence of blindness was also noted (conventional 38.8% vs.
intensive 29.3%) if progression from normal to retinopathy for
hypertensive patients with moderate control was assumed to be
faster, as in adults [10]. If intensive hypertension control is
applied for those with hypertension after 10 years of diabetes
and it affects progression of retinopathy, lifetime cumulative
incidence of blindness is somewhat attenuated (conventional
26.2% vs. intensive 19.6%). While the absolute reduction in
incidence of blindness with intensive glycaemic control was
greater in the adult scenarios, percentage reduction was similar
to the base case. For peripheral neuropathy, cumulative inci-
dence increased to 52.4% and 67.1% in the intensive and
conventional treatment groups, respectively, if the faster adult
rate of progression to peripheral neuropathy was applied after
10 years of diabetes compared with 22.6% and 31.7%,
respectively, in the base case. This also led to a slightly higher
cumulative incidence of lower extremity amputation (intensive
6.0% vs. conventional 7.8%). Finally, assuming a higher
baseline estimate of abnormal blood pressure (145 ⁄90) for
those with hypertension resulted in a higher lifetime cumulative
incidence of CHD in conventional and intensive treatment
groups (35.6% vs. 37.7%, respectively). If intensive glycaemic
control was assumed to reduce the risk of CHD by 16.0%, as
in the UKPDS [15], intensively-treated patients would have a
lower cumulative incidence of CHD compared with the base
case (intensive 32.3% vs. conventional 34.0%).
Results of multi-way sensitivity analyses are presented in the
Supporting Information, Table S1 (on-line appendix). When
significant microvascular disease was assumed to be present at
diagnosis and all microvascular complications progressed more
quickly than the base case, RLE was 39.77 years and QALE
was 18.65 QALYs. When no microvascular disease was
assumed to be present at diagnosis and all microvascular
complications progressed more slowly than the base case, RLE
was 45.76 years and QALE was 23.90 QALYs. With these
scenarios, the lifetime cumulative incidence of mortality caused
by ESRD differed from the base case by an increase or decrease
of approximately 10–15%, respectively. In the multi-way
sensitivity analyses, compared with the base case, lifetime
cumulative incidence of CHD could be higher as a result of
prolonged survival as well as poorer glycaemic control at
diagnosis or a higher estimate of abnormal blood pressure for
those with hypertension, both of which influenced the initial
the risk of developing CHD in the model.
Discussion
The natural history of Type 2 diabetes in US youth remains
uncertain. Previous research suggests that one in three males and
two in five females born in the USA in 2000 will develop diabetes
over their lifetime [12]. To our knowledge, this is the first study to
use modelling to describe the clinical outcomes associated
specifically with Type 2 diabetes diagnosed among US adoles-
cents ⁄young adults. While the absolute burden of Type 2 dia-
betes in youth remains small [1–5], our findings suggest that
adolescents ⁄young adults with Type 2 diabetes carry a high risk
of microvascular and macrovascular complications that shorten
life expectancy and reduce health-related quality of life. With
projected RLE of 43 years, youths diagnosed with Type 2 dia-
betes between 15 and 24 years old only live into their 60s com-
pared with the average 20-year-old in the USA with RLE of
58.6 years, living into his ⁄her 70s [28]. Our findings are consis-
tent with a previous Markov-modelling study demonstrating a
loss in RLE of 17.9 years for females and 17.2 years for males
diagnosed with diabetes at age 20 [12]. However, we also
describe the diabetes-related complications contributing to these
trends. Adult studies suggest that diabetes complications signif-
icantly increase medical costs [29], and our findings suggest
diabetes diagnosed in youth, regardless of intensity of glycaemic
control, may add to economic and societal costs by the intro-
duction of complications in the 40s and 50s.
Our model results demonstrated that intensive glycaemic
control introduced at diagnosis of Type 2 diabetes in adolescents
and young adults produces only modest improvements in RLE
and QALE. However, longer survival can lead to a slightly higher
lifetime cumulative incidence of macrovascular complications
and deaths owing to macrovascular complications. Our multi-
way sensitivity analyses further demonstrated that a higher life-
time cumulative incidence of CHD could be the result of either a
longer life expectancy or greater severity of risk factors that
contribute to the development of CHD. Focusing on aggressive
early control of cardiovascular risk factors, such as through
weight management, glycaemic control and treatment of
hypertension, beginning in adolescence and young adulthood
may be needed to reduce the longer term risk of CHD [30–32].
Such a strategy would be supported by recent randomized con-
trolled trials in adults, which have demonstrated that patients
with Type 2 diabetes of shorter duration and without established
cardiovascular disease are most likely to experience cardiovas-
cular benefits from intensive glycaemic control [30,33].
Adolescents with, or at risk of Type 2 diabetes, assign greater
loss in quality of life to intensive treatment, assumed here to
include treatment with insulin, than to a conventional treat-
ment with diet. When desirability of treatment was considered
in this fashion, intensive treatment with insulin resulted in net
loss of QALE. Our findings are conceptually consistent with
Huang et al. [34,35], who demonstrated disutility for insulin
treatment among adults with Type 2 diabetes and an impact on
the cost-effectiveness of treatments for Type 2 diabetes based
on the assumptions made about the patient preferences for
diabetes treatment [35]. This pattern is not unique to diabetes.
For primary prevention of cardiovascular disease in women,
Pignone et al. [36] demonstrated that, if the utility of taking
aspirin were < 0.9995, aspirin would be less effective than no
treatment. However, as adolescent and young adult preferences
may differ from those of older adults [27,34], future research is
ª 2011 The Authors.
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needed that incorporates age-specific utilities for diabetes
treatments to inform strategies that optimize QALE and
cost-effectiveness. The RTI Model adapted for the Youth
Model did not allow for changes in preferences over time.
Modelling, such as our Youth Model, provides information
about long-term health outcomes without the time investment
of an epidemiological study. However, our Youth Model relies
on current data regarding Type 2 diabetes in adolescents ⁄young
adults, including some areas for which only limited data exist.
Sensitivity analyses identified parameters with the most influ-
ence on the Youth Model outcomes, and about which addi-
tional research may be warranted to confirm our findings. We
found that rates of progression of microvascular disease, par-
ticularly retinopathy, influenced outcomes of conventional
Min Adolescent Utilities
Faster Progression of Retinopathy
Faster Progression of Neuropathy
Faster Progression of Nephropathy
Baseline Retinopathy 10%
Hypertensives Progress Faster
Adult Utilities (Ref 10)
Adult Utilities (Ref 34)
Baseline HbA1c 10.9%
Framingham CHD Model
Baseline Microalbuminuria 40%
Intensive Hypertension Control
–10 –8 –6 –4 –2 0 2 4 6 8 10
Percent Change in QALYs
Base Case
Baseline HbA1c 6.8% 
Baseline Microalbuminuria 0% 
Max Adolescent Utilities 
Slower Progression to Retinopathy (Photocoagulation) 
Faster Progression of Nephropathy with Hypertension 
Adult Retinopathy Progression after 10 Yrs
Slower Progression to Microalbuminuria 
HbA1c Change 0.18%/Yr
Baseline HbA1c 6.8%
Max. Adolescent Utilities
Faster Progression of Retinopathy
Hypertensives Progress Faster
Intensive Rx Reduces CHD Risk
Years From Onset to Diagnosis (0-2)
Faster Progression of Neuropathy
Adult Utilities (Ref 34)
Intensive Hypertension Control
Adult Utilities (Ref 10)
Adult Retinopathy Progression after 
10 Y
Max A1c with Conventional (11-13%)
Baseline Retinopathy 10%
Baseline Microalbuminuria 40% Baseline Microalbuminuria 0% 
Faster Progression of Nephropathy
Slower Progression to 
Microalbuminuria
Intensive Hypertension Control 
Affects Retinopathy
Slower Progression to Neuropathy 
–100 –80 –60 –40 –20 0 20 40 60 80 100
Percent Change in QALYs
Base Case
Min. Adolescent Utilities
HbA1c Change Conventional 0.24%/Yr; Intensive 0.2%/Yr
Framingham CHD Model
Slower Progression to Retinopathy (Photocoagulation)
Baseline HbA1c 10.9%
HbA1c Change 0.72%/Yr
Faster Progression of Nephropathy with Hypertension
(a)
(b)
FIGURE 3 Sensitivity analyses representing percentage change from base case. (a) Conventional treatment; (b) Incremental benefit of intensive glycaemic
control. Faster progression refers to the following hazard rates (HR): normal to retinopathy (photocoagulation) 0.04; normal to microalbuminuria 0.42;
normal to neuropathy 0.4702; all other HR represent a 20% increase from base case. Faster progression of nephropathy with hypertension refers to HR for
nephropathy transitions that are 20% above base case for those with hypertension with moderate control. Hypertensives progressing faster leads to faster
progression from normal to retinopathy at the adult HR = 0.0166. Intensive hypertension control leads to reduced risk of coronary heart disease (CHD)
and stroke. When applicable, intensive hypertensive control reduces progression to retinopathy applying adult HR after 10 years of diabetes. Slower
progression to microalbuminuria refers to HR = 0.042; Slower progression to retinopathy (photocoagulation) refers to HR = 0.001. Slower progression to
neuropathy refers to HR = 0.0019. Base case in Fig. (a) = 22.44 quality-adjusted life years (QALYs); Base case in (b) = 0.44 QALYs. Rx, treatment;
references for HR are included in the Supporting Information, Technical Report S1 (eTable 33).
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treatment. Many of the studies on early progression of micro-
vascular disease in youth with Type 2 diabetes are retrospective
and offer incomplete data, which may bias outcomes. Larger,
prospective and complete assessments of retinopathy screening
and follow-up in youth with Type 2 diabetes can inform future
modelling. With regard to intensive treatment, we found that a
higher HbA1c at diagnosis and faster annual increase in HbA1c
would support greater benefit from intensive treatment. While
data are available regarding the HbA1c at presentation [37],
little published data are available to inform HbA1c progression
beyond the first year after diagnosis in youths with Type 2
diabetes [18,38]. One study of 59 predominantly African-
American youths from Philadelphia, PA, USA, has shown that
glycaemic control improves in the first year of treatment but
deteriorates in the second year with variable rates of change
over time [38]. Future modelling, which accounts for greater
complexity in the longitudinal changes in HbA1c as well as for
possible differences in outcomes by gender, race ⁄ ethnicity,
hypertension status, and other characteristics at diagnosis may
need to be explored. Owing to the limits of available data, we
were unable to assess such differences in this study. As this
analysis was an adaptation of an adult model (the RTI Model),
certain parameters, such as the age range of our cohort
(15–24 years), were also fixed. As heterogeneity may exist
within this age range, additional analyses addressing the dif-
ferences that may exist within these subgroups may also be
needed. Finally, the adolescent utilities used in the Youth
Model were derived from a sample that included both adoles-
cents with Type 2 diabetes and those at risk [27]. While dif-
ferences in preferences could exist across these groups, the
utilities did not differ significantly by diagnosis in this popu-
lation sample [27].
The results of the Youth Model are based on the glycaemic
control achieved with intensive and conventional interventions
used in the UKPDS, which was an average HbA1c of
53 mmol ⁄mol (7.0%) and 63 mmol ⁄mol (7.9%), respectively
[15]. Glycaemic control within this range has been documented
for youths with Type 2 diabetes in the SEARCH for Diabetes in
Youth Study [18] making the interventions used in the Youth
Model relevant. However, some of the specific treatments used
in the UKPDS, including sulphonylureas and diet therapy [15],
are not the most common treatment approaches used for
adolescents with Type 2 diabetes [39]. Metformin is the most
common initial oral hypoglycaemic agent used in this popula-
tion as it is the only oral medication for treatment of Type 2
diabetes approved for use in children in the USA [40]. There-
fore, future models incorporating data from the metformin arm
of the UKPDS [41] or large trials specifically evaluating treat-
ments for Type 2 diabetes in youth, such as the TODAY
(Treatment Options for Type 2 Diabetes in Adolescents &
Youth) Study [42], may facilitate further study of interventions
specific to youths. As the focus of this analysis was on the
adolescent ⁄young adult cohort, we did not address updates to
the adult component of the RTI Model [10,13], which has
undergone recent validation [13].
In summary, we found that adolescents ⁄young adults diag-
nosed with Type 2 diabetes lose approximately 15 years from
average RLE and experience severe complications of Type 2
diabetes by their 40s. Intensive glycaemic control has modest
effects on life expectancy and the net clinical benefit of inter-
ventions to improve glycaemic control may be sensitive to
preferences for diabetes treatments. Comprehensive treatment
that includes early and aggressive control of multiple cardio-
vascular risk factors is likely needed to reduce the lifetime risk
of CHD in adolescents and young adults diagnosed with Type
2 diabetes.
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